Studies related to Apolipoprotein B and Hesperidin

Effects Of Glucosyl Hesperidin On Serum Lipids In Hyperlipidemic Subjects: Preferential Reduction In Elevated Serum Triglyceride Level

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 40
Gender Male
Age Range 18-29, 30-44, 45-64
Body Types Overweight
Notes for this study:
In hyperlipidemic men given either 100mg or 500mg of G-Hesperidin, there appeared to be more responders to a reduction in triglycerides (45-55% of the sample at both doses) and less responders for total cholesterol, LDL, and HDL (less than 20% of the sample getting more than a 10% reduction, and whole group effects failing to be statistically significant). The overall reduction in triglycerides for the whole group was only significant for the higher dose, and only occurred in the persons with higher triglycerides at baseline, and a reduction in LDL atherogenicity was thought to occur due to a decrease in Apolipoprotein B.

Glucosyl Hesperidin Lowers Serum Triglyceride Level In Hypertriglyceridemic Subjects Through The Improvement Of Very Low-density Lipoprotein Metabolic Abnormality

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 25
Gender Male
Age Range 18-29, 30-44, 45-64
Body Types Overweight, Average
Notes for this study:
500mg of G-hesperidin daily taken prior to bedtime for 24 weeks in hyperlipidemic patients was able to suppress triglycerides in serum up to 34%, but this suppression was normalized upon 4 weeks of cessation which returned to normal levels and only occurred in those with a baseline TG value above 150mg/dL. HDL was unaffected, while total cholesterol and LDL were mildly decreased and normalized to baseline upon cessation of the supplement, and the particule size of LDL was increased (suggesting a reduction in the atherogenic small and oxidized LDL).

Citrus Polyphenol Hesperidin Stimulates Production Of Nitric Oxide In Endothelial Cells While Improving Endothelial Function And Reducing Inflammatory Markers In Patients With Metabolic Syndrome

Effect Decrease
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 24
Gender Both Genders
Age Range 45-64
Body Types Obese
Notes for this study:
500mg of hesperidin daily for three weeks in persons with metabolic syndrome (in a double blind crossover study) was able to significantly improve blood flow as assessed by flow mediated vasodilation (24.5%) as well as inflammatory biomarkers such as C-reactive protein (33%), serum amyloid A (23%), and E-selectin (13%) while there was no influence on blood pressure, VCAM-1, or ICAM and a minor decrease in Apolipoprotein B (2.3%) while the increase in insulin sensitivity measured at less than 1% as assessed by QUICKI failed to reach significance (P=0.06)